![Page 1: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/1.jpg)
Jonathan C. Cohen
University of Texas SouthwesternMedical Center
A Short History of PCSK9From Discovery to Clinical Trials
![Page 2: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/2.jpg)
Disclosures
PfizerRegeneron
MerckRocheEli Lilly
Speaker/Consultant:
![Page 3: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/3.jpg)
Timeline: From Discovery to Clinical Trials2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 4: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/4.jpg)
Discovery: PCSK9 Mutations Cause Dominant LDL
Segregation of Chr 1p34.1−p32
Pedigree of family HC92
Nat Genet, 2003 (Boileau)
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 5: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/5.jpg)
S127R D374Y
PCSK9 Mutations Cause Dominant LDL
Nat Genet, 2003 (Boileau)Proc Natl Acad Sci, 2003 (Seidah)
Autocatalytic cleavage
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 6: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/6.jpg)
Overexpression of PCSK9 Eliminates LDLRs in Liver and Increases LDL-C
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
J Biol Chem, 2004 (Horton);Proc Natl Acad Sci , 2004 (Breslow); J Biol Chem, 2004 (Seidah)
![Page 7: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/7.jpg)
LDL
LDL
LDL
Gain of Function (GOF) mutations LDL
Loss of Function (LOF) mutation LDLHypothesis
- S127R- D374Y
J Biol Chem, 2004 (Horton);Proc Natl Acad Sci , 2004 (Breslow); J Biol Chem, 2004 (Seidah)
Normal Function of PCSK9 to Promote Degradation of LDLRs
LDL receptorLiver
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
PCSK9
LDL
LDL LDL
![Page 8: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/8.jpg)
<5%
Dallas Heart Studyn = 3,557
50% African-AmericanLDL-C
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
N - - C
African-Americans2%
Do LOF Mutations in PCSK9 Lower LDL?
![Page 9: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/9.jpg)
LOF Mutations in PCSK9 Lower LDL-C
European-Americans3%
African-Americans2%
LDL : 21% 40%
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
N - - C
![Page 10: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/10.jpg)
Plasma Cholesterol Levels are Reduced in PCSK9 KO Mice
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 11: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/11.jpg)
CHD Deaths(per 1000 / 10 y)
PCSK9 Mutations: A Tool to Test Role of LDL-Cholesterol in CHD Risk
Does Higher LDL-C Alone ExplainDifference between Shanghai and MRFIT?
![Page 12: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/12.jpg)
Mendelian Randomization
= No DNA sequence variant
= DNA sequence variant that alters LDL-C level
VSCompare CHD in
![Page 13: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/13.jpg)
LOF Mutations in PCSK9 Lower CHD
LDL: 28%
African-Americans
CHD:(over 15 y)
88%
Lancet, 2007 (McPherson)NEJM, 2008 (Katherisan)
15%
European-Americans
46%
ARIC Study (NIH): Eric Boerwinkle
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 14: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/14.jpg)
LDL-Lowering and Reduction in CHD
Reduction in LDL-C
Reduction in CHD
-10%
-100%
-50%
-10% -20% -30%0
Linsel-Nitchke et al. PlosOne, 2008Willer et al. Nat Gen, 2008;
APOBSORT1
LDLR
Statins - 5 y
PCSK9
PCSK9
R46L
Y142XC679X
![Page 15: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/15.jpg)
Phenotype(LDL level) Genotype(s)
Static Integrated • chronic exposure• single measurement
0 y
80 y
Genotypes Capture Another Dimension: Time
Cumulative LDL-C: mg/dL X years
![Page 16: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/16.jpg)
PCSK9: From Genes to Public HealthA little too little
Year
LDL
Goa
l
100
140
'87 '93 '0160
'04
NCEP Guidelines
A little too late
40 50 60 70
Ris
k R
educ
tion
(%)
Age at Onset of Rx (years)
30
?
![Page 17: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/17.jpg)
A Healthy Woman with No PCSK9
PCSK9in blood
Age (y): 51
32
53
6 3
10
Healthy, college graduate & aerobic instructor (now 38 y)
Zimbabwe: 21 y woman pregnant woman. LDL=16 mg/dL Hooper et al., Atherosclerosis 193:445
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 18: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/18.jpg)
Discovery
Target Validation3 Years
PCSK9: New Target for LDL-Lowering & CHD Prevention
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 19: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/19.jpg)
PCSK9: Target for LDL-Lowering
STATINS SREBP2(transcription
factor) LDLR
PCSK9
LDL• Efficacy • Safety (?)• Mechanism of action ?
![Page 20: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/20.jpg)
Parabiosis in Mice
PCSK9 acts extracellularly
J Clin Invest, 2006 (Horton)
PCSK9-Tg WTImmunoblot of liver proteins
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 21: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/21.jpg)
Normal Arh-/-
- PCSK9
+ PCSK9
PCSK9 Promotes LDLR Degradation in Hepatocytes
![Page 22: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/22.jpg)
PCSK9
LDLR
C-terminalDomain
CatalyticDomain
Prodomain
Nat Struc Mol Bio, 2007 (Pfizer); Structure, 2007 (Amgen) ; Proc Natl Acad Sci, 2007 (Novartis); Proc Natl Acad Sci, 2008 (Diesenhofer)
PCSK9 Crystal Structure
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 23: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/23.jpg)
Adapted from Brown and Goldstein
LDL
PCSK9 & LDL Receptor
J Biol Chem, 2004 (Horton)Proc Natl Acad Sci, 2005 (Breslow)
![Page 24: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/24.jpg)
Therapeutic Approaches to Inhibit PCSK9 Action
1. Inhibit enzymatic activity Small molecule
2. Disrupt PCSK9:LDLR interaction Anti-PCSK9 antibody Peptides or small molecule
3. Inhibit PCSK9 synthesis RNAi Anti-sense RNA
![Page 25: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/25.jpg)
mAb(primates)
Proc Natl Acad Sci, 2008 J Lipid Res, 2007
Proc Natl Acad Sci, 2009
ASO(mice)
RNAi(primates)
Inhibiting PCSK9 Lowers LDL-C in Animals….
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 26: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/26.jpg)
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 27: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/27.jpg)
Evolocumab (AMG 145) in Patients with Hypercholesterolemia (MENDEL-2)
Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Koren et al. J. Am. Coll. Cardiol. 2014. In press.
![Page 28: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/28.jpg)
Alirocumab (REGN727) + Statin in Pt’s with Hypercholesterolemia
(Randomized, Double-blind, Placebo-controlled, Phase 2 Study)
Roth EM et al. 2012. N Engl J Med. 367:1891-1900
![Page 29: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/29.jpg)
siRNA to Silence PCSK9(Phase I)
Fitzgerald et al. 2014. Lancet. 2014. 383:60-68.
![Page 30: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/30.jpg)
PCSK9: From Discovery to Clinical Trialsin 7 Years
Discovery
Target Validation3 Years
Target Validation
Phase I4 Years
Outcomes
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 31: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/31.jpg)
JCC Seminars: From Discovery to History in 7 Years
Phase 1“Genetics of
PCSK9”
Phase 2“Mechanism of
Action of PCSK9”
Phase 3“A Short History
Of PCSK9”
2003 2004 2005 2006 2007 2008 20102009 2011 2012 2013
![Page 32: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/32.jpg)
Human Genetics & Translation
• Selection of target - Lessons from lipoproteins
• Leveraging human genetic variation- Target validation- Target safety- ‘Goldilocks’ alleles (low frequency,large effect size)
• Genetics coupled to biological expertise
![Page 33: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/33.jpg)
Is PCSK9 Paradigmatic or Exceptional?
Both.
Exceptional in the narrow sense (few relatively common alleles with large effects on disease).
Paradigmatic in the broad sense (more alleles, lower frequency, moderate effects on disease).
![Page 34: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/34.jpg)
0
40
80
120
LDL‐C TG HDL‐C
ANGPTL3 +/FsANGPTL3 +/+P=0.03
P=0.08
P=0.53
2009: Frameshift Mutations in ANGPTL3 and Lipoprotein Levels in the Dallas Heart Study
mg/dl
![Page 35: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/35.jpg)
2010: Mutations in ANGPTL3 Cause Hypolipidemia*
TG: 51 98 LDL: 73 99HDL: 33 35
TG: 24 22 17 19 LDL: 35 31 29 37HDL: 16 16 22 18
*Musunuru et. al. NEJM
![Page 36: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/36.jpg)
Time
- Male sex- LDL- Diabetes- Smoking- Hypertension- HDL
Complex Diseases Are Not Necessarily So Complex
*Age 50 y
LDL X Time = Cumulative ExposureRx
• Diet• Lipid-lowering meds
![Page 37: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/37.jpg)
University of Texas Southwestern Medical Center
Helen HobbsJay D. Horton
NIH PO1 HL20948 – Year 35D.W. Reynolds FoundationHoward Hughes Medical Institute
![Page 38: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/38.jpg)
FPLC – fasting refeeding
FPLC of Plasma From Angptl8-/- Mice
![Page 39: University of Texas Southwestern Medical Center - Lipid · PDF fileJonathan C. Cohen University of Texas Southwestern Medical Center A Short History of PCSK9 From Discovery to Clinical](https://reader038.vdocuments.site/reader038/viewer/2022110221/5a71dd307f8b9a93538d4dae/html5/thumbnails/39.jpg)
Reduced Fat Mass in Angptl8-/- Mice
* P < 0.05** P < 0.01No significant differences (indirect calorimetry- 5 d)
• Food intake• O2 consumption• RER• Activity